Quince Therapeutics ROE 2024

Τι κάνει η Quince Therapeutics;

Cortexyme Inc. is a biotechnology company specializing in the development of therapies for degenerative diseases of the nervous system, particularly Alzheimer's disease. The company was founded in 2012 in South San Francisco by Casey Lynch and Stephen Dominy and has since become a leading company in this field. The origin of Cortexyme stems from the discovery of a new bacteria, Porphyromonas gingivalis (P. gingivalis), made by Lynch, the CEO of Cortexyme. He found that P. gingivalis is present in the vicinity of brain plaques in Alzheimer's patients. This discovery meant that Cortexyme had opportunities to develop prevention and treatment options for degenerative diseases of the nervous system. Cortexyme's business model is based on a combination of R&D (research and development) and precision medicine, enabling them to develop personalized therapy approaches. The company is working to specifically target therapeutic molecules against bacteria associated with Alzheimer's and develop biological solutions that target the bacteria. Cortexyme collaborates with a range of specialists, scientists, and university laboratories to conduct their research. The company also has its own research department focused on the discovery of therapeutics to inhibit or eliminate the growth of P. gingivalis. The company has various divisions focusing on the discovery and development of therapeutics. One division focuses on developing biomarkers to aid the diagnosis of Alzheimer's. Another division is developing targeted antibiotics against P. gingivalis, while a third division focuses on developing therapeutics that inhibit the breakdown of bacteria and plaque in the brain. Cortexyme has also developed several products, including the Alzheimer's drug program Atuzaginstat (COR388), which is currently in Phase III of clinical development. Atuzaginstat aims to inhibit P. gingivalis and has the potential to provide hope to terminally ill Alzheimer's patients. Cortexyme is also working on other products, including COR569 to combat inflammation associated with cognitive decline and COR271 to eliminate bacteria that promote brain inflammation. Overall, Cortexyme has taken a new direction in the exploration of Alzheimer's treatment by investigating the role of bacteria in the disease and developing new therapeutic approaches. The company has positioned itself as a leader in Alzheimer's research and will continue to work on developing innovative therapies and prevention strategies that improve the quality of life for Alzheimer's patients and enhance hope for a cure. Quince Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.